Skip to content

Catheter ablation versus antiarrhythmic drug therapy for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy

Catheter ablation versus antiarrhythmic drug therapy for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076819
Enrollment
Unknown
Registered
2023-10-19
Start date
2023-10-20
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic cardiomyopathy patients with sustained ventricular tachycardia

Interventions

Ablation group (patients who underwent catheter ablation):NA
AAD group (patients who received AAD therapy):NA

Sponsors

The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The study population includes 28 HCM patients with sustained VT, age 18 to 80 years old.

Exclusion criteria

Exclusion criteria: Patients with prior VT ablation, Patients with malignant tumors or hematological diseases with a life expectancy of less than 1 year, Patients with incomplete data, Patients who didn’t visit for routine follow-up.

Design outcomes

Primary

MeasureTime frame
VT recurrence;

Secondary

MeasureTime frame
hospital admission due to cardiovascular (CV) cause;CV cause-related mortality, or heart transplantation;the composite endpoint of VT recurrence, hospital admission due to CV cause, CV cause-related mortality, or heart transplantation.;

Countries

China

Contacts

Public ContactZhang Fengxiang

The First Affiliated Hospital of Nanjing Medical University

njzfx6@163.com+86 139 5203 7301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026